ICON Public (NASDAQ:ICLR) Price Target Cut to $160.00 by Analysts at Robert W. Baird

ICON Public (NASDAQ:ICLR - Get Free Report) had its price target reduced by equities research analysts at Robert W. Baird from $192.00 to $160.00 in a report released on Friday,Benzinga reports. The brokerage currently has a "neutral" rating on the medical research company's stock. Robert W. Baird's price target suggests a potential upside of 14.88% from the company's previous close.

ICLR has been the topic of a number of other reports. Barclays reaffirmed an "equal weight" rating and set a $165.00 price target (down from $240.00) on shares of ICON Public in a report on Thursday, April 10th. Truist Financial reduced their target price on shares of ICON Public from $262.00 to $208.00 and set a "buy" rating for the company in a report on Thursday, April 10th. Mizuho dropped their price objective on ICON Public from $238.00 to $200.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. Citigroup reduced their target price on ICON Public from $290.00 to $215.00 and set a "buy" rating on the stock in a report on Monday, April 7th. Finally, William Blair reiterated an "outperform" rating on shares of ICON Public in a research report on Tuesday, January 14th. Eight investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $215.33.

ICON Public Stock Performance

Shares of ICON Public stock traded up $4.17 during trading hours on Friday, reaching $139.27. The company had a trading volume of 1,003,205 shares, compared to its average volume of 986,593. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.26 and a quick ratio of 1.34. The firm has a market cap of $11.25 billion, a PE ratio of 14.61, a price-to-earnings-growth ratio of 1.86 and a beta of 1.23. ICON Public has a one year low of $133.28 and a one year high of $347.72. The business has a fifty day simple moving average of $162.87 and a 200 day simple moving average of $193.26.

ICON Public (NASDAQ:ICLR - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The medical research company reported $3.19 earnings per share for the quarter, beating analysts' consensus estimates of $3.17 by $0.02. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. The business had revenue of $2 billion for the quarter, compared to the consensus estimate of $2.03 billion. During the same quarter last year, the business posted $3.47 earnings per share. The company's revenue for the quarter was down 4.3% on a year-over-year basis. On average, analysts anticipate that ICON Public will post 13.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ICON Public

A number of large investors have recently modified their holdings of ICLR. GAMMA Investing LLC increased its stake in shares of ICON Public by 64.0% in the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company's stock worth $91,000 after acquiring an additional 169 shares during the period. Steph & Co. boosted its stake in shares of ICON Public by 3.7% in the fourth quarter. Steph & Co. now owns 1,560 shares of the medical research company's stock worth $327,000 after buying an additional 55 shares during the last quarter. Park Place Capital Corp grew its holdings in ICON Public by 281.4% during the fourth quarter. Park Place Capital Corp now owns 225 shares of the medical research company's stock worth $47,000 after acquiring an additional 166 shares during the period. Avior Wealth Management LLC lifted its holdings in ICON Public by 76.0% in the fourth quarter. Avior Wealth Management LLC now owns 894 shares of the medical research company's stock valued at $187,000 after acquiring an additional 386 shares during the period. Finally, Tributary Capital Management LLC grew its stake in shares of ICON Public by 116.1% during the 4th quarter. Tributary Capital Management LLC now owns 3,950 shares of the medical research company's stock worth $828,000 after purchasing an additional 2,122 shares during the period. Hedge funds and other institutional investors own 95.61% of the company's stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.